{"id":390855,"date":"2017-11-15T00:00:00","date_gmt":"2017-11-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0001-2017-biopharma-alzheimers-disease-disease-landscape-and-forecast-g7-2017\/"},"modified":"2026-04-22T23:28:30","modified_gmt":"2026-04-22T23:28:30","slug":"dlsfcg0001-2017-biopharma-alzheimers-disease-disease-landscape-and-forecast-g7-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0001-2017-biopharma-alzheimers-disease-disease-landscape-and-forecast-g7-2017\/","title":{"rendered":"Alzheimer’s Disease | Disease Landscape and Forecast | G7 | 2017"},"content":{"rendered":"

The market for Alzheimer\u2019s disease (AD<\/abbr>) pharmacotherapies represents an enormous commercial opportunity driven by considerable unmet need and looming societal burden. The\u00a0AD<\/abbr>\u00a0population is poised to grow rapidly over the next ten years as the baby boomer generation ages, simultaneously increasing the treatable patient pool and straining healthcare resources. Moreover, approved treatments today comprise a handful of symptomatic therapies that offer only modest efficacy of limited duration. Two critical unmet needs in\u00a0AD<\/abbr>\u00a0treatment remain: the development of bona fide disease-modifying therapies (DMT<\/abbr>s) that are capable of slowing disease progression, and the launch of improved symptomatic adjuncts, including those for behavioral deficits. Despite a perennially high rate of attrition, the late-phase pipeline in\u00a0AD<\/abbr>\u00a0remains full and diverse, comprising a range of promising symptomatic and disease-modifying candidates. At this time, we forecast the launch of four\u00a0potential\u00a0DMT<\/abbr>s targeting the amyloid cascade\u2014 Roche\/Genentech\/AC Immune\u2019s crenezumab, Biogen\/Neurimmune\u2019s aducanumab, Biogen\/Eisai\u2019s\u00a0elenbecestat, and Merck\u2019s verubecestat\u2014which will dramatically expand the\u00a0AD<\/abbr>\u00a0market. Additionally, we forecast the launch of two behavioral therapies, Lundbeck\/Otsuka\u2019s Rexulti and Avanir\u2019s AVP-786\u00a0for the treatment of agitation associated with\u00a0AD<\/abbr>. However, owing to as-yet uncertain clinical benefits for any emerging candidates, and lingering questions about the clinical efficacy, safety, and fundamental launch prospects\u00a0of putative\u00a0DMT<\/abbr>s, we expect investigational products will only partially fulfill the need for therapeutic advances should they launch, leaving ample room for superior alternatives.<\/p>\n

QUESTIONS ANSWERED<\/p>\n